The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Flow Cyt: Use 0.5µg for 106 cells in 100µl volume.
IHC-P: Use at an assay dependent dilution.
IP: Use at an assay dependent dilution.
WB: Use at an assay dependent dilution. Predicted molecular weight: 13 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival.
Restricted in the T-cell lineage to immature thymocytes and activated peripheral lymphocytes. Preferentially expressed early in T- and B-lymphocyte differentiation.
Involvement in disease
Note=Chromosomal aberrations activating TCL1A are found in chronic T-cell leukemias (T-CLL). Translocation t(14;14)(q11;q32); translocation t(7;14)(q35;q32); inversion inv(14)(q11;q32) that involves the T-cell receptor alpha/delta loci.
Staining of Daudi cells with ab91211 at 0.25 µg (blue histogram), or purified Mouse IgG2b, isotype control at 0.25 µg (green histogram), followed by treatment with Biotin anti-Mouse IgG and Phycoerythrin (PE) Streptavidin. Total viable cells were used for analysis.